Predicting Survival of Patients with Nonmetastatic Breast Cancer Based on Fibrinogen-to-Albumin Ratio and Lymphocyte-to-Monocyte Ratio: A Nomogram-Based Assessment.

IF 2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Breast Care Pub Date : 2023-10-01 Epub Date: 2023-07-26 DOI:10.1159/000531939
Xiao-Yu Chen, Zhi-Qing Long, Han-Ying Huang, Wen Wen, Fei Lin, Ling Guo, Huan-Xin Lin
{"title":"Predicting Survival of Patients with Nonmetastatic Breast Cancer Based on Fibrinogen-to-Albumin Ratio and Lymphocyte-to-Monocyte Ratio: A Nomogram-Based Assessment.","authors":"Xiao-Yu Chen,&nbsp;Zhi-Qing Long,&nbsp;Han-Ying Huang,&nbsp;Wen Wen,&nbsp;Fei Lin,&nbsp;Ling Guo,&nbsp;Huan-Xin Lin","doi":"10.1159/000531939","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Parameters of systemic inflammation have received attention as prognostic surrogates in various malignant tumors. Fibrinogen-to-albumin ratio (FAR) and lymphocyte-to-monocyte ratio (LMR) correlate with tumor growth and dissemination. We aimed to bring the combination of FAR and LMR (FAR-LMR) together to establish novel nomograms for survival and recurrence in nonmetastatic breast cancer patients.</p><p><strong>Methods: </strong>We retrospectively recruited 461 female patients with nonmetastatic breast cancer from January 2011 to December 2013 in our hospital and randomly assigned them into the training cohort (<i>N</i> = 318) and the validation cohort (<i>N</i> = 143). The potential predictive factors for overall survival (OS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were assessed by Cox proportional hazards models and log-rank test.</p><p><strong>Results: </strong>Elevated FAR was associated with poor OS (<i>p</i> < 0.001) and DMFS (<i>p</i> = 0.02), whereas increased LMR was associated with satisfactory OS (<i>p</i> = 0.01) and LRFS (<i>p</i> = 0.01). High FAR combined with low LMR was associated with less favorable OS (<i>p</i> = 0.001), LRFS (<i>p</i> = 0.005), and DMFS (<i>p</i> = 0.003) Based on multivariate analysis, FAR-LMR, tumor size, lymph node metastasis, age, and pathologic status contributed to prognostic nomograms of OS, DMFS, and LRFS. Nomograms presented exceptional performance for 3-, 5-, and 8-year OS, DMFS, and LRFS prediction compared with clinical TNM stage. The C-index was significantly higher than that of TNM stage, either of FAR or LMR (3-year: 0.709 vs. 0.621 vs. 0.544 vs. 0.641, 5-year: 0.761 vs. 0.597 vs. 0.605 vs. 0.677, 8-year: 0.84 vs. 0.62 vs. 0.539 vs. 0.623).</p><p><strong>Conclusions: </strong>We developed and validated a convenient predictive model for the survival outcomes of patients with nonmetastatic breast cancer. The nomograms can be utilized as auxiliary tools to provide prognostic information.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601685/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000531939","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Parameters of systemic inflammation have received attention as prognostic surrogates in various malignant tumors. Fibrinogen-to-albumin ratio (FAR) and lymphocyte-to-monocyte ratio (LMR) correlate with tumor growth and dissemination. We aimed to bring the combination of FAR and LMR (FAR-LMR) together to establish novel nomograms for survival and recurrence in nonmetastatic breast cancer patients.

Methods: We retrospectively recruited 461 female patients with nonmetastatic breast cancer from January 2011 to December 2013 in our hospital and randomly assigned them into the training cohort (N = 318) and the validation cohort (N = 143). The potential predictive factors for overall survival (OS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were assessed by Cox proportional hazards models and log-rank test.

Results: Elevated FAR was associated with poor OS (p < 0.001) and DMFS (p = 0.02), whereas increased LMR was associated with satisfactory OS (p = 0.01) and LRFS (p = 0.01). High FAR combined with low LMR was associated with less favorable OS (p = 0.001), LRFS (p = 0.005), and DMFS (p = 0.003) Based on multivariate analysis, FAR-LMR, tumor size, lymph node metastasis, age, and pathologic status contributed to prognostic nomograms of OS, DMFS, and LRFS. Nomograms presented exceptional performance for 3-, 5-, and 8-year OS, DMFS, and LRFS prediction compared with clinical TNM stage. The C-index was significantly higher than that of TNM stage, either of FAR or LMR (3-year: 0.709 vs. 0.621 vs. 0.544 vs. 0.641, 5-year: 0.761 vs. 0.597 vs. 0.605 vs. 0.677, 8-year: 0.84 vs. 0.62 vs. 0.539 vs. 0.623).

Conclusions: We developed and validated a convenient predictive model for the survival outcomes of patients with nonmetastatic breast cancer. The nomograms can be utilized as auxiliary tools to provide prognostic information.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于纤维蛋白原与白蛋白比率和淋巴细胞与单核细胞比率预测非转移性乳腺癌患者的生存:一种基于nomogram评估
背景:全身炎症参数作为各种恶性肿瘤的预后指标受到关注。纤维蛋白原与白蛋白比率(FAR)和淋巴细胞与单核细胞比率(LMR)与肿瘤生长和扩散相关。我们的目的是将FAR和LMR(FAR-LMR)结合在一起,以建立非转移性癌症患者生存和复发的新列线图。方法:我们回顾性招募了2011年1月至2013年12月在我院就诊的461名女性癌症非转移患者,并将她们随机分为训练队列(N=318)和验证队列(N=143)。通过Cox比例风险模型和对数秩检验评估总生存率(OS)、局部无复发生存率(LRFS)和无远处转移生存率(DMFS)的潜在预测因素。结果:FAR升高与OS差(p<0.001)和DMFS(p=0.02)相关,而LMR升高与OS满意(p=0.01)和LRFS(p<0.01)相关。高FAR联合低LMR与OS较差(p=0.001)、,病理状态有助于OS、DMFS和LRFS的预后列线图。与临床TNM分期相比,诺模图在3年、5年和8年OS、DMFS和LRFS预测方面表现出色。C指数显著高于FAR或LMR的TNM分期(3年:0.709对0.621对0.544对0.641,5年:0.761对0.597对0.605对0.677,8年:0.84对0.62对0.539对0.623)。列线图可以用作辅助工具来提供预后信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Breast Care
Breast Care 医学-妇产科学
CiteScore
4.40
自引率
4.80%
发文量
45
审稿时长
6-12 weeks
期刊介绍: ''Breast Care'' is a peer-reviewed scientific journal that covers all aspects of breast biology. Due to its interdisciplinary perspective, it encompasses articles on basic research, prevention, diagnosis, and treatment of malignant diseases of the breast. In addition to presenting current developments in clinical research, the scope of clinical practice is broadened by including articles on relevant legal, financial and economic issues.
期刊最新文献
ASCO 2024: Personal Insights and a Look into the Future from an International Expert Group. Association of Aromatase Inhibitor-Induced Musculoskeletal Symptoms with Central Sensitization-Related Symptoms: A Cross-Sectional Study. Vitamin D and breast cancer risk: evaluating the association and effective risk reduction Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes Using Low-Cost Dual Dye Technique: Identifying Factors Associated with Adequate False Negative Rate Threshold. Translating Evidence into Practice: A Review of Clinical Practice and Outcomes following the Adoption of an Early Post-Mastectomy Discharge Protocol in a Nigerian Hospital.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1